Brief: Akeso Receives First Tranche Of $300 Mln Upfront Payment From Summit As Part Of Deal
26/01/2023 14:37
Jan 26 (Reuters) - Akeso Inc 9926.HK :
* AKESO RECEIVED FIRST TRANCHE OF US$300 MILLION UPFRONT
PAYMENT
FROM SUMMIT! SUMMIT IS ACCELERATING CLINICAL DEVELOPMENT OF
IVONESCIMAB
Source text for Eikon: ID:nPn99dnJZa
Further company coverage: 9926.HK
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akeso
See all newsBrief: Akeso Announces Summit Therapeutics And Ecog-Acrin Cancer Research Group Enter Into Phase Ii/Iii Clinical Trial Collaboration To Evaluate Ivonescimab In First-Line Biliary Tract Cancer
Factbox: Major drugmakers turn to China for licensing deals
HK-listed Akeso drops most in nearly three months on discounted share sale
Brief: Akeso To Place 20 Million New Shares At HK$97.76 Per Share
Factbox: Major drugmakers turn to China for licensing deals